Chengdu Zenitar Biomedical Technology Co., Ltd

This Phase 2 trial tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The drug is given by IV four times per 21-day cycle for up to 96 weeks. The main goal is to see if it can shrink tumors…

This study tests a new drug called purinostat mesylate in 74 adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or not responded to treatment). The goal is to see if the drug can shrink tumors and control the disease, while…